368 related articles for article (PubMed ID: 26821505)
1. [INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
Shouval R; Livneh A; Ben-Zvi I
Harefuah; 2015 Nov; 154(11):716-9, 741. PubMed ID: 26821505
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
4. Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis.
Sozeri B; Kasapcopur O
Curr Med Chem; 2015; 22(16):1986-91. PubMed ID: 25760087
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
[TBL] [Abstract][Full Text] [Related]
6. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
Gül A
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
[TBL] [Abstract][Full Text] [Related]
7. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G; Jawad A; Uthman I
Orphanet J Rare Dis; 2019 Oct; 14(1):224. PubMed ID: 31615541
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
[TBL] [Abstract][Full Text] [Related]
9. Biologic therapy in familial Mediterranean fever.
Koga T; Migita K; Kawakami A
Mod Rheumatol; 2016 Sep; 26(5):637-41. PubMed ID: 26939747
[TBL] [Abstract][Full Text] [Related]
10. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
Front Immunol; 2020; 11():971. PubMed ID: 32670263
[No Abstract] [Full Text] [Related]
11. Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.
Portincasa P; Scaccianoce G; Palasciano G
Eur J Clin Invest; 2013 Dec; 43(12):1314-27. PubMed ID: 24117178
[TBL] [Abstract][Full Text] [Related]
12. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
Sargin G; Kose R; Senturk T
Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269
[TBL] [Abstract][Full Text] [Related]
14. [Familial Mediterranean fever: not to be missed].
Frenkel J; Bemelman FJ; Potter van Loon BJ; Simon A
Ned Tijdschr Geneeskd; 2013; 157(18):A5784. PubMed ID: 23635502
[TBL] [Abstract][Full Text] [Related]
15. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure.
Stankovic Stojanovic K; Delmas Y; Torres PU; Peltier J; Pelle G; Jéru I; Colombat M; Grateau G
Nephrol Dial Transplant; 2012 May; 27(5):1898-901. PubMed ID: 21931121
[TBL] [Abstract][Full Text] [Related]
16. IL-1β biological treatment of familial Mediterranean fever.
Soriano A; Verecchia E; Afeltra A; Landolfi R; Manna R
Clin Rev Allergy Immunol; 2013 Aug; 45(1):117-30. PubMed ID: 23322405
[TBL] [Abstract][Full Text] [Related]
17. A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever.
Corsia A; Georgin-Lavialle S; Hentgen V; Hachulla E; Grateau G; Faye A; Quartier P; Rossi-Semerano L; Koné-Paut I
Orphanet J Rare Dis; 2017 Mar; 12(1):54. PubMed ID: 28302131
[TBL] [Abstract][Full Text] [Related]
18. IL-1 blockers together with colchicine may be administered as first line therapy in familial Mediterranean fever with amyloidosis.
Tezcan ME
Med Hypotheses; 2019 Sep; 130():109269. PubMed ID: 31383341
[TBL] [Abstract][Full Text] [Related]
19. Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients.
Akar S; Cetin P; Kalyoncu U; Karadag O; Sari I; Cınar M; Yilmaz S; Onat AM; Kisacik B; Erden A; Balkarli A; Kucuksahin O; Oner SY; Senel S; Tufan A; Direskeneli H; Oksuz F; Pehlivan Y; Bayindir O; Keser G; Aksu K; Omma A; Kasifoglu T; Unal AU; Yildiz F; Balci MA; Yavuz S; Erten S; Ozgen M; Sayarlıoglu M; Dogru A; Yildirim G; Oner FA; Tezcan ME; Pamuk ON; Onen F
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1090-1094. PubMed ID: 28992387
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.
Calligaris L; Marchetti F; Tommasini A; Ventura A
Eur J Pediatr; 2008 Jun; 167(6):695-6. PubMed ID: 17588171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
